Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 21 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 544009 | NSE: BLUEJET

Fundamental Analysis of Blue Jet Healthcare Ltd

Basic Stock Data

Last Updated: July 20, 2024, 10:11 pm

Market Cap 7,050 Cr.
Current Price 406
High / Low447/319
Stock P/E41.2
Book Value 48.7
Dividend Yield0.00 %
ROCE30.0 %
ROE22.4 %
Face Value 2.00
PEG Ratio-12.14

Data Source: screener.in

Competitors of Blue Jet Healthcare Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Industry Average0 Cr0000%0%0%0

Quarterly Result

MonthJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Sales145190169217180181167184
Expenses106132117147121119112131
Operating Profit3859527059635553
OPM %27%31%31%32%33%35%33%29%
Other Income476658-39
Interest00000000
Depreciation66766688
Profit before tax3659517058644454
Tax %24%26%27%27%24%26%27%27%
Net Profit2844385144483240
EPS in Rs1.612.532.162.922.542.761.852.29

Last Updated: July 11, 2024, 8:28 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: July 10, 2024, 10:19 pm

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales538499683721712
Expenses325292434502482
Operating Profit214207249219229
OPM %40%41%36%30%32%
Other Income69192419
Interest75310
Depreciation1820222528
Profit before tax194190243217220
Tax %25%26%25%26%26%
Net Profit145142182160164
EPS in Rs24,118.331,428.5710.479.239.44
Dividend Payout %0%0%0%0%11%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-2.07%28.17%-12.09%2.50%
Change in YoY Net Profit Growth (%)0.00%30.24%-40.26%14.59%

Growth

Compounded Sales Growth
10 Years:%
5 Years:%
3 Years:13%
TTM:-1%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:7%
TTM:7%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:%
1 Year:%
Return on Equity
10 Years:%
5 Years:%
3 Years:28%
Last Year:22%

Last Updated: July 17, 2024, 4:45 pm

Balance Sheet

Last Updated: July 10, 2024, 10:19 pm

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital110353535
Reserves198330487647811
Preference Capital0200
Borrowings74521952
Other Liabilities92145173176212
Total Liabilities3645367138621,059
Fixed Assets1070156151172
CWIP23330147
Investments263794189250
Other Assets229497460491489
Total Assets3645367138621,059

Reserves and Borrowings Chart

Cash Flow

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 122137146142241
Cash from Investing Activity -45-61-76-147-264
Cash from Financing Activity -72-21-56-4-2
Net Cash Flow55514-10-24

Free Cash Flow

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow140.00154.00230.00214.00227.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days8010512112191
Inventory Days120201133137151
Days Payable90101725835
Cash Conversion Cycle110204183199206
Working Capital Days64105105121213
ROCE %58%52%35%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2023Mar 2024
Promoters86.00%86.00%
FIIs2.93%2.01%
DIIs3.70%3.04%
Public7.37%8.97%
No. of Shareholders55,58948,625

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund1,080,4131.0137.17367,3442024-07-19194.11%
ICICI Prudential Innovation Fund732,0670.625.18367,3442024-07-1999.29%
HDFC Business Cycle Fund367,3440.4312.64367,3442024-07-190%
Bandhan Small Cap Fund285,3910.229.82367,3442024-07-19-22.31%
Edelweiss Recently Listed IPO Fund231,4030.847.96367,3442024-07-19-37.01%
Edelweiss Aggressive Hybrid Fund144,4800.374.97367,3442024-07-19-60.67%
Edelweiss Aggressive Hybrid Fund - Plan B144,4800.374.97367,3442024-07-19-60.67%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 21Mar 20
FaceValue100.00100.00
Basic EPS (Rs.)1396.271462.59
Diluted EPS (Rs.)1396.271462.59
Cash EPS (Rs.)1568.3027166.33
Book Value[Excl.RevalReserv]/Share (Rs.)3428.3432238.33
Book Value[Incl.RevalReserv]/Share (Rs.)3428.3432238.33
Revenue From Operations / Share (Rs.)5033.6189699.16
PBDIT / Share (Rs.)2168.4336589.16
PBIT / Share (Rs.)1970.0533582.66
PBT / Share (Rs.)1862.9632354.50
Net Profit / Share (Rs.)1369.9224159.83
NP After MI And SOA / Share (Rs.)1396.4324141.33
PBDIT Margin (%)43.0740.79
PBIT Margin (%)39.1337.43
PBT Margin (%)37.0136.07
Net Profit Margin (%)27.2126.93
NP After MI And SOA Margin (%)27.7426.91
Return on Networth / Equity (%)40.7375.40
Return on Capital Employeed (%)52.3283.21
Return On Assets (%)25.9438.58
Long Term Debt / Equity (X)0.080.19
Total Debt / Equity (X)0.100.30
Asset Turnover Ratio (%)1.100.00
Current Ratio (X)2.431.89
Quick Ratio (X)1.691.37
Inventory Turnover Ratio (X)2.300.00
Interest Coverage Ratio (X)40.4929.79
Interest Coverage Ratio (Post Tax) (X)27.5820.67

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 458.43

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 12.91% compared to the current price 406

Intrinsic Value: 380.39

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Overvalued: 6.31% compared to the current price 406

Last 5 Year EPS CAGR: -17.02%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock is trading at a low valuation with an average P/B ratio of 17,776.36 and average Dividend Yield of 38.28%.
  2. The stock has a high average ROCE of 29.00%, which is a positive sign.
  3. The company has higher reserves (494.60 cr) compared to borrowings (30.60 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (630.60 cr) and profit (212.80 cr) over the years.
  1. The stock has a high average Working Capital Days of 121.60, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 180.40, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Blue Jet Healthcare Ltd:
    1. Net Profit Margin: 27.21%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 52.32% (Industry Average ROCE: %)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 40.73% (Industry Average ROE: %)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 27.58
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.69
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 41.2 (Industry average Stock P/E: )
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.10
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Pharmaceuticals
INDUSTRYADDRESSCONTACT
701, 702, 7th Floor, Bhumiraj Costarica, Thane Maharashtra 400705Mr.Akshay%20Bansarilal%20Arora
Executive%20Chairman
Management
NamePosition Held
Mr. Shiven Akshay AroraManaging Director
Mr. Naresh Suryakant ShahExecutive Director
Mr. Girish Paman VanvariIndependent Director
Ms. Preeti Gautam MehtaIndependent Director
Ms. Divya Sameer MomayaIndependent Director

FAQ

What is the latest fair value of Blue Jet Healthcare Ltd?

The latest fair value of Blue Jet Healthcare Ltd is ₹458.43.

What is the Market Cap of Blue Jet Healthcare Ltd?

The Market Cap of Blue Jet Healthcare Ltd is 7,050 Cr..

What is the current Stock Price of Blue Jet Healthcare Ltd as on 21 July 2024?

The current stock price of Blue Jet Healthcare Ltd as on 21 July 2024 is 406.

What is the High / Low of Blue Jet Healthcare Ltd stocks in FY 2024?

In FY 2024, the High / Low of Blue Jet Healthcare Ltd stocks is 447/319.

What is the Stock P/E of Blue Jet Healthcare Ltd?

The Stock P/E of Blue Jet Healthcare Ltd is 41.2.

What is the Book Value of Blue Jet Healthcare Ltd?

The Book Value of Blue Jet Healthcare Ltd is 48.7.

What is the Dividend Yield of Blue Jet Healthcare Ltd?

The Dividend Yield of Blue Jet Healthcare Ltd is 0.00 %.

What is the ROCE of Blue Jet Healthcare Ltd?

The ROCE of Blue Jet Healthcare Ltd is 30.0 %.

What is the ROE of Blue Jet Healthcare Ltd?

The ROE of Blue Jet Healthcare Ltd is 22.4 %.

What is the Face Value of Blue Jet Healthcare Ltd?

The Face Value of Blue Jet Healthcare Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Blue Jet Healthcare Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE